Nucleic Acid Therapeutics Global Market Report 2026
상품코드:1957518
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
핵산 치료제 시장 규모는 최근 급성장하고 있습니다. 2025년 69억 4,000만 달러에서 2026년에는 80억 1,000만 달러에 이르고, CAGR 15.4%의 성장이 전망되고 있습니다. 지난 몇 년간 성장 요인으로는 핵산 치료제품공급 제한, 기존 저분자 치료제에 대한 의존도, 정밀의료에 대한 수요 증가, 초기 단계의 유전자 치료에 대한 규제 당국의 승인, 유전자 조절에 대한 학술적 연구 증가 등을 들 수 있습니다.
핵산 치료제 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 140억 7,000만 달러에 이르고, CAGR은 15.1%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 CRISPR을 비롯한 유전자 편집 기술 개발, 지질 나노입자(LNP) 전달 시스템 확대, 개인 맞춤형 핵산 치료법 채택 증가, 제약사와 바이오 기업 간 협력 강화, RNA 기반 치료제 투자 확대 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 안티센스 올리고뉴클레오티드(ASO) 및 siRNA 치료제의 도입 증가, CRISPR 기반 및 유전자교정 치료제의 확대, 신경근육질환, 대사질환, 종양질환에 대한 표적치료제의 성장, 비바이러스 및 바이러스성 전달시스템에 대한 비바이러스성 및 바이러스성 전달 시스템에 대한 투자 증가, 장쇄 비암호화 RNA(lncRNA) 및 마이크로 RNA(miRNA) 치료제의 출현 등이 있습니다.
유전성 질환 및 만성 질환의 유병률 증가는 핵산 치료제 시장의 성장을 가속할 것으로 예측됩니다. 유전성 질환 및 만성질환은 유전적 요소와 당뇨병, 심장질환, 암, 자가면역질환 등 지속성 질환의 발병, 진행 및 감수성 사이의 상호작용을 의미합니다. 이러한 증가는 주로 이러한 질병을 보다 정확하고 빠르게 감지할 수 있는 진단 도구의 발전으로 인한 것입니다. 핵산 치료제는 유전자 조절, 수정, 억제를 통해 근본적인 유전적 요인에 작용하여 표적화된 맞춤 의료를 제공함으로써 유전성 질환 및 만성질환에 효과를 발휘합니다. 예를 들어, 2024년 10월 영국 낭포성 섬유증 환자 지원 단체인 낭포성 섬유증 트러스트(Cystic Fibrosis Trust)가 발표한 자료에 따르면, 2022년 등록 환자 수는 11,148명이었으나, 2023년에는 11,318명으로 증가해 전년 대비 1.5% 상승했습니다. 이처럼 유전성 질환 및 만성질환 증가 추세가 핵산 치료제품 시장을 견인하고 있는 것입니다.
핵산치료제 시장의 주요 기업들은 질병 관련 유전자를 특정하고 불활성화시키는 안티센스 올리고뉴클레오티드 요법 등 새로운 솔루션을 개발하여 유전성 질환 및 희귀질환에 대한 정밀 치료제를 제공합니다. 안티센스 올리고뉴클레오티드 요법은 인위적으로 합성된 짧은 DNA 또는 RNA 사슬을 이용하여 질병 관련 유전자의 발현을 억제하거나 변형시키는 치료법입니다. 예를 들어, 2024년 12월 미국 바이오기업 아이오니스 파마슈티컬스는 가족성 킬로미크로네미아 증후군(FCS)을 가진 성인의 트리글리세리드(중성지방)를 낮추기 위한 식이 보조제 TRYNGOLZ(올레자르센)의 FDA 승인을 받았습니다. 승인을 받았습니다. FCS는 극도의 고중성지방혈증(SHTG)과 급성 췌장염(AP) 위험 증가를 특징으로 하는 희귀 유전성 질환입니다. 저지방 식단과 함께 사용하면 이 환자군에서 지속적인 중성지방 감소와 급성 췌장염 발생률을 현저하게 감소시켜 FDA가 승인한 최초의 치료 옵션입니다. 본 치료는 자동주사기를 이용한 간단한월1회 자가주사로 시행할 수 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 TAM(Total Addressable Market) 규모
제9장 시장 세분화
제10장 지역별/국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업 및 혁신 기업
제38장 세계 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병(M&A)
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
LSH
영문 목차
영문목차
Nucleic acid therapeutics are a class of treatments that use nucleic acids, including deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or their synthetic analogues, to modulate gene expression or correct genetic mutations, enabling disease treatment at the molecular level. These therapies employ synthetic DNA or RNA strands to precisely target and regulate specific genetic sequences, offering solutions for diseases that are difficult to address with conventional drugs.
The main therapy types of nucleic acid therapeutics include antisense oligonucleotides (ASOs), small interfering RNA (siRNA), gene therapies, aptamers, and others. Antisense oligonucleotides (ASOs) are short, synthetic nucleic acid strands that bind to specific messenger RNA (mRNA) molecules to block or modify the expression of target genes. Nucleic acid therapeutics are applied across multiple therapeutic areas, including neuromuscular disorders, metabolic disorders, cardiovascular diseases, ophthalmological disorders, and oncology. They are administered through various routes such as intravenous and subcutaneous injections and utilize different delivery methods, including viral vector-based and non-viral systems. Key end users of these therapies include pharmaceutical companies, biotechnology firms, and government and academic research institutions.
Tariffs have affected the nucleic acid therapeutics market by increasing the cost of imported raw materials, viral vectors, lipid nanoparticles, and advanced synthesis reagents. Segments such as gene therapies and RNA-based therapeutics are most impacted, particularly in regions like North America and Europe, which rely heavily on imports from Asia-Pacific. While tariffs have increased operational costs and slowed supply chains, they have also encouraged domestic manufacturing, investment in local R&D, and innovation in cost-effective delivery systems.
The nucleic acid therapeutics market research report is one of a series of new reports from The Business Research Company that provides nucleic acid therapeutics market statistics, including nucleic acid therapeutics industry global market size, regional shares, competitors with a nucleic acid therapeutics market share, detailed nucleic acid therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the nucleic acid therapeutics industry. This nucleic acid therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The nucleic acid therapeutics market size has grown rapidly in recent years. It will grow from $6.94 billion in 2025 to $8.01 billion in 2026 at a compound annual growth rate (CAGR) of 15.4%. The growth in the historic period can be attributed to limited availability of nucleic acid therapeutics, reliance on traditional small molecule therapies, growing demand for precision medicine, regulatory approvals for early gene therapies, increasing academic research on gene modulation.
The nucleic acid therapeutics market size is expected to see rapid growth in the next few years. It will grow to $14.07 billion in 2030 at a compound annual growth rate (CAGR) of 15.1%. The growth in the forecast period can be attributed to development of crispr and other gene editing technologies, expansion of lipid nanoparticle (lnp) delivery systems, rising adoption of personalized nucleic acid therapies, increasing collaborations between pharma and biotech, growing investment in rna-based therapeutics. Major trends in the forecast period include rising adoption of antisense oligonucleotides (asos) and sirna therapies, expansion of crispr-based and gene editing therapeutics, growth in targeted therapies for neuromuscular, metabolic, and oncological disorders, increasing investment in non-viral and viral delivery systems, emergence of long non-coding rna (lncrna) and microrna (mirna) therapeutics.
The mounting prevalence of genetic and chronic diseases is poised to drive the nucleic acid therapeutics market forward. Genetic and chronic diseases encompass the interplay between hereditary genetic elements and the onset, advancement, or susceptibility to enduring ailments like diabetes, heart conditions, cancer, and autoimmune issues. This escalation mainly results from enhanced diagnostic tools that detect these disorders more precisely and promptly. Nucleic acid therapeutics prove valuable for genetic and chronic diseases by addressing root genetic drivers-through gene regulation, correction, or suppression-delivering targeted, individualized care. For instance, in October 2024, the Cystic Fibrosis Trust, a UK charity aiding cystic fibrosis patients, reported 11,148 registered cases in 2022, rising to 11,318 in 2023-a 1.5% year-on-year jump in registrations. Thus, the growing burden of genetic and chronic diseases is spurring the nucleic acid therapeutics market.
Prominent firms in the nucleic acid therapeutics market are advancing novel solutions like antisense oligonucleotide therapy to pinpoint and mute disease-linked genes, providing exact treatments for genetic and rare conditions. Antisense oligonucleotide therapy employs brief, lab-made DNA or RNA strands to inhibit or alter expression of disease-related genes. For example, in December 2024, Ionis Pharmaceuticals Inc., a US biotech company, secured FDA approval for TRYNGOLZ (olezarsen) as a dietary adjunct to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare genetic condition marked by extreme hypertriglyceridemia (sHTG) and elevated acute pancreatitis (AP) risk. It marks the inaugural FDA-endorsed option for substantial, lasting triglyceride drops in this group, plus notable AP reductions paired with a low-fat diet. The treatment supports easy monthly self-injection via auto-injector.
In June 2025, Novartis AG, a Switzerland-based innovator in drug development and production, acquired Regulus Therapeutics Inc. for an undisclosed sum. This deal seeks to fortify Novartis's RNA-targeted drug expertise, enrich its portfolio for rare and chronic diseases, and hasten next-gen therapies leveraging Regulus's microRNA prowess. Regulus Therapeutics Inc. is a US biotech firm dedicated to microRNA-based therapies.
Major companies operating in the nucleic acid therapeutics market are Pfizer Inc., Novartis AG, Moderna Inc., BioNTech SE, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., CureVac SE, Sangamo Therapeutics Inc., Beam Therapeutics Inc., Arbutus Biopharma Corporation, Silence Therapeutics plc, Copernicus Therapeutics Inc.
North America was the largest region in the nucleic acid therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nucleic acid therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the nucleic acid therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The nucleic acid therapeutics market consists of revenues earned by entities by providing services such as custom oligonucleotide synthesis, gene silencing and editing services, drug discovery and development support, messenger RNA (mRNA) and small interfering RNA (siRNA) design and optimization, and delivery system development. The market value includes the value of related goods sold by the service provider or included within the service offering. The nucleic acid therapeutics market also includes sales of messenger RNA (mRNA) therapeutics, clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing tools (therapeutic use), aptamers, and Amondys 45 (casimersen). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Nucleic Acid Therapeutics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses nucleic acid therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for nucleic acid therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The nucleic acid therapeutics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Therapy Type: Antisense Oligonucleotides (ASOs); Small Interfering RNA (siRNA); Gene Therapies; Aptamers; Other Therapy Types
2) By Therapeutic Area: Neuromuscular Disorder; Metabolic Disorders; Cardiovascular Disorders; Ophthalmological Disorders; Oncological Disorders; Other Therapeutic Areas
3) By Route Of Administration: Intravenous; Subcutaneous; Other Route Of Administrations
4) By Delivery Method: Viral Vector-Based Delivery Systems; Non-Viral Delivery Systems
5) By End-Use: Pharmaceutical Companies; Government And Academic Research Institutes; Biotech Companies
Subsegments:
1) By Antisense Oligonucleotides (ASOs): Phosphorothioate ASOs; 2'-O-Methyl ASOs; Locked Nucleic Acid (LNA) ASOs; Gapmer ASOs; Morpholino ASOs
2) By Small Interfering RNA (siRNA): Lipid Nanoparticle (LNP) Formulated siRNA; GalNAc-Conjugated siRNA; Chemically Modified siRNA; Naked siRNA
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
4.2.1 Rising Adoption Of Antisense Oligonucleotides (Asos) And Sirna Therapies
4.2.2 Expansion Of Crispr-Based And Gene Editing Therapeutics
4.2.3 Growth In Targeted Therapies For Neuromuscular, Metabolic, And Oncological Disorders
4.2.4 Increasing Investment In Non-Viral And Viral Delivery Systems
4.2.5 Emergence Of Long Non-Coding Rna (Lncrna) And Microrna (Mirna) Therapeutics
5. Nucleic Acid Therapeutics Market Analysis Of End Use Industries
5.1 Pharmaceutical Companies
5.2 Biotech Companies
5.3 Government And Academic Research Institutes
5.4 Clinical Research Organizations (Cros)
5.5 Hospitals And Specialty Treatment Centers
6. Nucleic Acid Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Nucleic Acid Therapeutics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Nucleic Acid Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Nucleic Acid Therapeutics Market Size, Comparisons And Growth Rate Analysis
7.3. Global Nucleic Acid Therapeutics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Nucleic Acid Therapeutics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Nucleic Acid Therapeutics Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Nucleic Acid Therapeutics Market Segmentation
9.1. Global Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Antisense Oligonucleotides (ASOs), Small Interfering RNA (siRNA), Gene Therapies, Aptamers, Other Therapy Types
9.2. Global Nucleic Acid Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Neuromuscular Disorder, Metabolic Disorders, Cardiovascular Disorders, Ophthalmological Disorders, Oncological Disorders, Other Therapeutic Areas
9.3. Global Nucleic Acid Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Intravenous, Subcutaneous, Other Route Of Administrations
9.4. Global Nucleic Acid Therapeutics Market, Segmentation By Delivery Method, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Viral Vector-Based Delivery Systems, Non-Viral Delivery Systems
9.5. Global Nucleic Acid Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Pharmaceutical Companies, Government And Academic Research Institutes, Biotech Companies
9.6. Global Nucleic Acid Therapeutics Market, Sub-Segmentation Of Antisense Oligonucleotides (ASOs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.7. Global Nucleic Acid Therapeutics Market, Sub-Segmentation Of Small Interfering RNA (siRNA), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.8. Global Nucleic Acid Therapeutics Market, Sub-Segmentation Of Gene Therapies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.10. Global Nucleic Acid Therapeutics Market, Sub-Segmentation Of Other Therapy Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Segmentation By Therapeutic Area, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Nucleic Acid Therapeutics Market
12.1. China Nucleic Acid Therapeutics Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Segmentation By Therapeutic Area, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Nucleic Acid Therapeutics Market
13.1. India Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Segmentation By Therapeutic Area, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Nucleic Acid Therapeutics Market
14.1. Japan Nucleic Acid Therapeutics Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Segmentation By Therapeutic Area, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Nucleic Acid Therapeutics Market
15.1. Australia Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Segmentation By Therapeutic Area, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Nucleic Acid Therapeutics Market
16.1. Indonesia Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Segmentation By Therapeutic Area, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Nucleic Acid Therapeutics Market
17.1. South Korea Nucleic Acid Therapeutics Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Segmentation By Therapeutic Area, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Segmentation By Therapeutic Area, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Nucleic Acid Therapeutics Market
19.1. South East Asia Nucleic Acid Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Segmentation By Therapeutic Area, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Nucleic Acid Therapeutics Market
20.1. Western Europe Nucleic Acid Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Segmentation By Therapeutic Area, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Nucleic Acid Therapeutics Market
21.1. UK Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Segmentation By Therapeutic Area, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Nucleic Acid Therapeutics Market
22.1. Germany Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Segmentation By Therapeutic Area, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Nucleic Acid Therapeutics Market
23.1. France Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Segmentation By Therapeutic Area, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Nucleic Acid Therapeutics Market
24.1. Italy Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Segmentation By Therapeutic Area, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Nucleic Acid Therapeutics Market
25.1. Spain Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Segmentation By Therapeutic Area, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Nucleic Acid Therapeutics Market
26.1. Eastern Europe Nucleic Acid Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Segmentation By Therapeutic Area, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Nucleic Acid Therapeutics Market
27.1. Russia Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Segmentation By Therapeutic Area, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Nucleic Acid Therapeutics Market
28.1. North America Nucleic Acid Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Segmentation By Therapeutic Area, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Nucleic Acid Therapeutics Market
29.1. USA Nucleic Acid Therapeutics Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Segmentation By Therapeutic Area, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Segmentation By Therapeutic Area, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Nucleic Acid Therapeutics Market
31.1. South America Nucleic Acid Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Segmentation By Therapeutic Area, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Nucleic Acid Therapeutics Market
32.1. Brazil Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Segmentation By Therapeutic Area, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Nucleic Acid Therapeutics Market
33.1. Middle East Nucleic Acid Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Segmentation By Therapeutic Area, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Nucleic Acid Therapeutics Market
34.1. Africa Nucleic Acid Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Segmentation By Therapeutic Area, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Nucleic Acid Therapeutics Market Regulatory and Investment Landscape
36. Nucleic Acid Therapeutics Market Competitive Landscape And Company Profiles
